Segment Information

3 Months Ended

Dec. 31, 2022

Segment Reporting [Abstract]

Segment Information

12. Segment Information

Segment revenue, operating loss, and depreciation and amortization were as follows:

	Three Months Ended
	December 31,
(In thousands)	2022			2021
Revenue:
Medical Device	$	19,018		$	16,908
In Vitro Diagnostics		5,915			6,095
Total revenue	$	24,933		$	23,003
Operating (loss) income:
Medical Device	$	(7,235	)	$	(3,792	)
In Vitro Diagnostics		2,948			3,155
Total segment operating (loss) income		(4,287	)		(637	)
Corporate		(2,942	)		(2,804	)
Total operating (loss) income	$	(7,229	)	$	(3,441	)
Depreciation and amortization:
Medical Device	$	1,953		$	2,194
In Vitro Diagnostics		77			86
Corporate		92			96
Total depreciation and amortization	$	2,122		$	2,376

The Corporate category includes expenses that are not fully allocated to the Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to administrative corporate functions, such as executive management, corporate accounting, information technology, legal, human resources and Board of Directors. Corporate may also include expenses, such as acquisition-related costs and litigation, which are not specific to a segment and thus not allocated to the reportable segments.

Asset information by segment is not presented because the Company does not provide its chief operating decision maker assets by segment, as the data is not readily available.